MorphoSys AG (MPSYY.PK) Tuesday reported fourth-quarter consolidated profit of 3.2 million euros, compared to a loss of 4.8 million euros in the same period last year.
Earnings before interest and taxes, or EBIT, totaled 4.4 million euros, compared to a loss of 8.0 million euros last year.
Fourth-quarter included a loss of 0.1 million euros from discontinued operations.
Group revenues increased to 16.5 million euros from 12.3 million euros last year.
Operating expenses dropped to 12.2 million euros from 20.4 million euros last year.
Revenues and costs arising from the AbD Serotec segment are classified as discontinued operations, due to the sale of segment to Bio-Rad.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.